BioSpace News Archive

Technology removes carbon dioxide from industrial sources and the atmosphere

Fuse Medical, Inc., (OTCPK: FZMD), an emerging manufacturer and distributor of innovative medical devices for the orthopedic and spine marketplace, announced the results of its 2019 Annual Shareholder Meeting that was held on Wednesday, June 26, 2019.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the U.S. Food and Drug Administration (FDA) approved SOLIRIS® (eculizumab) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.

Integrated DNA Technologies (IDT) announces that it has entered into a strategic cooperation with ChosenMed Technology (Beijing) Co., Ltd (ChosenMed), a medical sequencing firm focused on personalized medicine and transformation healthcare in China.

Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, notes the announcement made today by Sierra Oncology (“Sierra”), the licence holder for novel oral Chk1 inhibitor SRA737, that it is exploring non-dilutive strategic options to support the future continued development of its portfolio of potent and selective DDR (DNA Damage Response) assets, including SRA737.

Ovid Therapeutics Inc. (NASDAQ: OVID), today announced that following a Type C Meeting with the U.S. Food and Drug Administration(FDA), it has initiated the pivotal Phase 3 NEPTUNE trial with OV101, a novel delta (δ)-selective GABAA receptor agonist, in Angelman syndrome

Austrian biotech company PhagoMed Biopharma GmbH successfully completed another financing round. PhagoMed, located at the Vienna Biocenter, is focused on developing virus-(phage-) based therapies against drug-resistant and chronic bacterial infections.